The Chinese Ministry of Health has found no clinical evidence to link Synutra’s infant milk products and premature breast growth in three infant girls.
Tests found no signs of inappropriate hormones and the Ministry said yesterday (15 August) that, when looking at similar cases of precocious puberty in recent years, there was no heightened risk of being affected through using infant formula compared to breast feeding.
The move follows a week of speculation in the Chinese media that hormones in infant formula from Chinese firm Synutra was responsible for the early development. Synutra has vehemently defended the safety of its products.
The Ministry said it did not find any unusual levels of hormones in the 73 samples it tested, of which 42 were Synutra’s milk, and one sample of milk residue from one of the infants’ homes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData